ATXS News & Events

BioCryst Pharmaceuticals (BCRX) announced that it has completed its acquisition of Astria Therapeutics (ATXS) initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema, HAE, and enhances the company's long-term growth trajectory. The acquisition was completed for an implied transaction value of approximately $700 million, net of Astria's cash at closing. BioCryst financed the cash portion of the acquisition with cash on hand and approximately $396.6 million drawn from a financing facility with funds managed by Blackstone. In addition, at the closing of the transaction, BioCryst issued approximately 37.3 million shares of its common stock to Astria's equity holders.

Astria Therapeutics, Inc. (ATXS) announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals (BCRX). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.

BioCryst Pharmaceuticals (BCRX) has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended with respect to BioCryst's proposed acquisition of Astria Therapeutics (ATXS). Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions.